Joe Wiley. Amryt

Com­ing out of Chap­ter 11, Aege­ri­on jumps in­to wel­come arms of Irish phar­ma with big plans, fresh $60M for its drugs

Am­ryt Phar­ma didn’t make much of a splash in May when it struck a deal to ac­quire Nov­e­l­ion’s Aege­ri­on sub­sidiary, ab­sorb­ing two com­mer­cial drugs and a US in­fra­struc­ture in an all-stock deal. But now that the trans­ac­tion has been wrapped, the Dublin-based com­pa­ny is ready to bring some re­newed at­ten­tion to it — as well as a fresh $60 mil­lion raise.

The fi­nanc­ing al­lows Am­ryt to con­tin­ue rolling out Myalep­ta in Eu­rope while al­so tak­ing over glob­al re­spon­si­bil­i­ties for the drug (known as Myalept in the US), which treats lipody­s­tro­phy, and a ho­mozy­gous fa­mil­ial hy­per­c­ho­les­terolemia ther­a­py called Jux­tapid/Lo­jux­ta. Am­ryt has been mar­ket­ing Lo­jux­ta in Eu­rope.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.